MaxCyte, Inc. (LON:MXCT - Get Free Report)'s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 325.72 ($4.36) and traded as low as GBX 295.50 ($3.96). MaxCyte shares last traded at GBX 302 ($4.04), with a volume of 3,510 shares.
MaxCyte Stock Down 1.3 %
The company has a market cap of £313.17 million, a P/E ratio of -1,115.38 and a beta of 1.13. The company has a quick ratio of 14.38, a current ratio of 14.31 and a debt-to-equity ratio of 8.37. The firm has a fifty day moving average price of GBX 325.72 and a 200 day moving average price of GBX 334.34.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Recommended Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
